Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer

被引：26

作者：

Burris, Howard A., III ^{[1
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN 37203 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2011年 / 11卷 / 06期

关键词：

GROWTH-FACTOR RECEPTOR; CLINICAL-PRACTICE GUIDELINES; BRAIN METASTASES; CARDIAC SAFETY; PHASE-II; LAPATINIB; COMBINATION; T-DM1; PROGRESSION; EFFICACY;

D O I：

10.1517/14712598.2011.580273

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Areas covered: The mechanisms of action, preclinical efficacy and clinical profile of T-DM1 are reported. The latest preclinical and clinical data for T-DM1 are examined. Expert opinion: T-DM1 has significant antitumor potency in vitro and in vivo, which is maintained in tumors resistant to trastuzumab or lapatinib. In Phase I and II trials, T-DM1 provided objective tumor responses and was well tolerated across various lines of therapy in patients with HER2-positive MBC. In addition, it showed similar efficacy to trastuzumab plus docetaxel in first-line MBC. Ongoing trials (including two Phase III studies) are investigating T-DM1 as single-agent therapy or combined with other chemotherapeutic or biologic agents, and the results should help to define the place of T-DM1 within current treatment algorithms for HER2-positive disease.

引用

页码：807 / 819

页数：13